Replay available

TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call

TransMedics Group, Inc. (NASDAQ: TMDX) Q4 2025 earnings conference call, held 2026-02-24. Replay captured from the company's public earnings webcast.

Tue, February 24, 2026 at 4:30 PMendedReplay
TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Josh Jennings

Analyst, TD Cowen

Laney Morgan

Investor Relations, Gilmartin Group

Suraj Kaila

Analyst, Oppenheimer & Co.

David Rescott

Analyst, Baird

Alan Gong

Analyst, J.P. Morgan Chase & Company

Bill Polvinich

Analyst, Canaccord Genuity

Gerardo Hernandez

Chief Financial Officer

Daniel Markovits

Analyst, Evercore ISI

Mike Macron

Analyst, Needham & Company

Waleed Hassaneen

President and Chief Executive Officer

Matthew Mardula

Analyst, William Blair (for Ryan Daniels)

Replay transcript excerpt

Good afternoon and welcome to Transmedic's fourth quarter 2025 earnings conference call. This time, all participants are in a listen-only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Laney Morgan from the Gilmartin Group for a few introductory comments. Thank you. Earlier today, Transmedics released financial results for the quarter and full year ended December 31st, 2025. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call, including during the question and answer portion of the call, that include forward-looking statements within the meaning of federal securities laws. Any statements made during this call that relate to future events, results, or performance, including expectations or predictions, are forward-looking statements. All forward-looking statements, including without limitation, our examination of operating trends, the potential commercial opportunity of our products and services, the potential timing, benefits, or outcomes of new clinical programs, and our future financial expectations, which include expectations for growth in our organization and guidance, and or expectations for revenue, gross margins, and operating expenses in 2026 and beyond, are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. Additional information rega...

More from Transmedics Group, Inc.